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Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disorder and 
the most common neurodegenerative disorder in the industrialized world. In 1906, 
Aloise Alzheimer, a German Psychiatrist, identified and presented the first case of a 
fifty-year-old woman called Auguste D. 
In the early stages of AD, the most commonly recognized symptom is the inability to 
acquire new memories, such as difficulty in recalling recently observed facts. Gradually, 
bodily functions are lost, ultimately leading to death. Individual prognosis is difficult to 
assess, and the duration of the disease varies. Neurodegeneration associated with AD 
develops for an indeterminate period of time before becoming clinically apparent, and it 
can progress undiagnosed for years. In fact, the cause and progression of AD are not 
well understood. When AD is suspected, the diagnosis is usually confirmed by 
behavioural assessments and cognitive tests, often followed by a brain scan.  
An internationally agreement upon standard of tests for AD clinical diagnosis includes a 
detailed history, functional measurement of cognitive decline such as instrumental 
activity of daily living scales, Mini Mental Status Examination test (MMSE), Clinical 
Dementia Rating (CDR), Disability Assessment for Dementia (DAD), 
neuropsychological evaluation, neurological and psychiatric examination.  
The MMSE test, for example, allows classifying subjects with dementia according to 
categories of clinical severity and to the rate of cognitive decline. This test, developed 
by Folstein in 1975, is widely used, since it provides a semi quantitative evaluation of 
the degree of cognitive impairment (Folstein et al. 1975).  
The cognitive evaluation obtained from this test is today accurate and reached up to 
90% of the confirmed autopsy cases. AD must be differentiated from other causes of 
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dementia: vascular dementia, dementia with Lewy bodies, Parkinson’s disease with 
dementia, fronto- temporal dementia, and reversible dementias.  
An intermediate stage between normal ageing and dementia has long been recognized 
by several classification systems and these attempts have viewed the condition as either 
physiological ageing or the beginnings of a pathological process and were defined as 
mild cognitive impairment (MCI) (Figure 1) (DeCarli 2003). 
 
 
Figure 1. Hypothetical model for the pathological-clinical continuum of AD (Sperling et al. 2011). 
 
The diagnosis of MCI is performed according to the following criteria: memory 
complaint, normal activities of daily living, normal general cognitive function, 
abnormal memory for age, and absence of dementia (Petersen 2004). It was been 
observed that MCI are likely to progress to AD at a rate of approximately 12% per year 
compared to 1 to 2% for cognitively normal people at the same age (Petersen et al. 
1999).  
Because not all individuals with MCI progress to clinical dementia, it is critical to 
identify risk factors and biomarkers for the development of AD in this cohort. So, 
Aggarwal et al. showed that the presence the ε4 variant of the allele for apolipoprotein E 
(APOE), a known risk factor for the development of AD in normal elderly individuals, 
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is also associated with increased risk of developing AD in individuals with MCI 
(Aggarwal et al. 2005).  
Cerebral atrophy can be detected during life with structural imaging techniques, such as 
magnetic resonance imaging (MRI) which allows the quantification of atrophy due to its 
ability to acquire high resolution images with good soft tissue contrast properties. 
Studies using MRI have identified different patterns of cerebral atrophy in different 
degenerative disorders. Subjects with AD typically show patterns of atrophy involving 
the medial temporal lobe, particularly the hippocampus and entorhinal cortex, and the 
posterior cingulate, precuneus and the tempo-parietal neocortex, with concurrent 
expansion of the ventricles. Subjects with MCI typically show similar, although less 
severe, patterns of atrophy such as those observed in AD (Whitwell 2010). 
 
 
 
Introduction 
 
7 
 
Epidemiology 
According to the World Health Organization it is estimated that 35.6 millions of people 
worldwide currently suffer AD. This number is expected to double by 2030 and more 
than triple by 2050. Dementia affects people in all countries; with more than half living 
in low- and middle-income countries and by 2050, this is likely to rise to more than 
70% (http://www.who.int/mediacentre/news/releases/2012 /dementia_ 20120411).  
North America and Western Europe have the highest prevalence of dementia (6.4% and 
5.4% of the population at age 60), followed by Latin America (4.9%) and China and its 
developing western-Pacific neighbours (4.0%). The prevalence rates for AD also rise 
exponentially with age, increasing markedly after 65 years. The annual incidence rates 
(per 1000 individuals in the population) for Western Europe was estimated at 8.8, 
increasing exponentially with age, especially through the seventh and eighth decades of 
life (Reitz et al. 2011).  
In Italy, AD patients are almost 1 million and the annual incidence is going to increase 
as a consequence of the progressive increase of the mean age and life expectancy in our 
population.  
Moreover AD is more prevalent in women than in men. The higher prevalence of AD in 
women is explained in part by differences in life expectancy between the genders (Vest 
et al. 2012). 
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Pathogenesis 
AD is characterized by a progressive decline in cognitive functions which typically 
begins with memory deterioration. In the final stage of the disease, individuals with this 
disorder have usually become dependent on caregivers. AD patients develop severe 
impairments in memory and executive cortical functions. Although living patients can 
be diagnosed clinically with possible or probable AD, a confirmed diagnosis requires 
post-mortem histological identification of neuropathological hallmarks. In figure 2 are 
shown time points at which preventive, disease modifying, and symptomatic 
interventions, respectively, are likely to be most effective, while in the upper bar are 
shown the identified milestones (genetic mutation, Aβ (amyloid-β peptide) and tau 
misfolding, oxidative and inflammatory stress and cell death) in the patho-biology of 
AD that culminates in death and autopsy confirmation of AD. 
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Figure 2. Hypothetical time line for the onset and progression of AD, neurodegeneration and cognitive 
impairments progressing from normal control to MCI and to AD (Trojanowski et al. 2010). 
 
AD begins with abnormal processing of amyloid precursor protein thereby increasing 
brain Aβ which leads to neuron dysfunction and death. The model also assumes a lag 
phase between Aβ deposition and neuron loss, and differences in brain resiliency, 
plasticity, cognitive reserve or other factors likely account for the variable duration of 
this lag phase (Trojanowski et al. 2010). 
The key pathological changes that are observed in AD brain tissue are increased levels 
of both the amyloid-β (Aβ) peptide, which is deposited extracellular in diffuse and 
neuritic plaques, and hyperphosphorylated tau (p-tau), a microtubule assembly protein 
that accumulates intracellular as neurofibrillary tangles (NFTs) (Figure 2). These 
neuropathological hallmarks are often accompanied by the presence of reactive 
microgliosis and widespread loss of neurons and synapses (Reitz et al. 2011). 
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The current view of AD pathogenetic mechanisms describes amyloid deposition and 
neuritic plaques formation as a central mechanism leading to neuro-degeneration, 
cognitive impairment and AD (Figure 2). APP (amiloid precursor protein) is the Aβ 
peptide precursor and is a trans-membrane glycoprotein widely expressed, produced by 
the endoplasmatic reticulum and involved in the neuronal and dendritic growth and 
synapses formation (Steuble et al. 2012). 
The metabolic cleavage of APP involves three different enzymes called α, β and γ 
secretase. APP gene encodes the amyloid precursor protein, which gives rise to Aβ, 
composed of 40-42 amino acids, through serial cleavage by β-secretase and γ-secretase. 
Proteolitic cleavage by α secretase prevents Aβ release and results in the so called non 
amyloidogenic pathway (Thinakaran et al. 2008). 
γ-secretase is a complex of four proteins in which the enzymatic components are 
encoded by the early-onset familial AD genes presenilin 1 (PSEN1) and presenilin 2 
(PSEN2). Aβ 40-42 peptide is the major form of Aβ produced during βAPP 
metabolism. In the pathogenesis of AD, accumulation of Aβ in the brain, particularly 
Aβ42, is considered to be an important step (Small et al. 1999). Aß40 is the major form 
of secreted Aβ. However, Aß42 aggregates more readily and is thought to seed amyloid 
fibril polymerization during the early stages of plaque formation (Jarrett et al. 1993).  
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Figure 3. Model of amiloidogenic cascade (Tanzi 2012). 
 
Once it has been generated, Aβ can be transported out of the brain with the assistance of 
ApoE. Alternatively, Aβ can undergo proteolytic degradation. As Aβ 40-42 accumulates 
it can aggregate, and this is influenced by ApoE. Aggregation into oligomers (for 
example, dimers and trimers) can lead to impairment of long-term potentiation (LTP). 
Aβ oligomers can further aggregate into fibrils, which might ultimately be deposited in 
senile plaques. Senile plaques and Aβ aggregates can induce inflammatory responses 
and oxidative stress. Transferrin (TF) regulates the metabolism of iron, a reactive metal 
that is involved in free-radical generation and, thus, in oxidative stress. Oxidative stress 
and iron have been associated with abnormal tau phosphorylation and aggregation, and 
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with the formation of NFTs. The principal component of NFTs is tau. Aβ oligomers 
have been reported to induce NFT formation. NFTs induce neuron death, which can 
result in further inflammation and oxidative stress. In turn, inflammation and oxidative 
stress can enhance further Aβ deposition, resulting in a vicious cycle (Bertram et al. 
2008). 
This model of AD views Aβ peptide accumulation as a key early event in the 
pathophysiological process of AD. However, the etiology of AD remains uncertain, and 
some investigators have proposed that synaptic, mitochondrial, metabolic, 
inflammatory, neuronal, cytoskeletal, and other age-related alterations may play an even 
earlier, or more central, role than Aβ peptides in the pathogenesis of AD. 
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Classification 
AD is usually classified according to its age of onset. The majority (>95%) of patients 
who develop this disease are aged >65 years (sporadic or late-onset AD), with 1–5% of 
AD cases exhibiting an earlier onset, typically in the late 40s or early 50s (familiar or 
early-onset AD). 
 
Familiar form of early onset AD (EOFAD) 
Approximately 5% of cases of AD are familial (autosomal dominant) and with an early 
age onset. In these cases, AD is caused by mutations in three genes: APP on 
chromosome 21, PSEN1 on chromosome 14, and the PSEN2 on chromosome 1 (Table 
1) (Tanzi 2012). 
Table 1. Early-onset familial Alzheimer disease genes and their pathogenic effects 
 
Sporadic form of late onset AD (LOAD) 
Late-onset Alzheimer is the most common form of the disease and it is defined by the 
age at onset after 65 years. Whereas EOFAD is characterized by classic Mendelian 
inheritance usually in an autosomal-dominant manner, LOAD is associated with a 
genetically complex pattern of inheritance in which genetic risk factors work together 
with environmental factors and life exposure events to determine lifetime risk for AD. 
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It is well established that the inheritance of the apolipoprotein E (APOE) ε4 allele is the 
single most potent and common genetic risk factor for LOAD (Tanzi 2012). The APOE 
gene is polymorphic, with three common alleles (ε 2, ε 3, ε 4), and in studies of the 
general population six genotypes are observed: 3/3, 4/3, 3/2, 4/4, 4/2, and 2/2. The three 
major alleles of the APOE locus, ε2, ε3, and ε4, correspond to combinations of two 
amino acid changes at residues 112 and 158 (ε2: Cys112/Cys158; ε3: Cys112/Arg158; 
ε4: Arg112/Arg158). APOE ε 4/4 increases the AD risk more than about 12-fold, and 
APOE ε3/4 about 3-fold when compared with the APOE ε 3/3 genotype (Koffie et al 
2012). In contrast, the APOE ε2 allele exerts “protective” effects (Corder et al. 1994). 
Synapse loss is a strong correlate of cognitive decline in Alzheimer’s disease and 
imaging studies have suggested the occurrence of synaptic dysfunction decades before 
AD onset in APOE ε4 patients. However, the mechanistic link between apoE isoform 
and these effects in AD remains unknown (Koffie et al 2012). 
Moreover many other genes, involved in different pathways, have been proposed as 
candidates for AD susceptibility.  Our previews studies showed the association of 
several SNPs (single nucleotide polymorphisms) in the promoter region of genes 
involved in the inflammatory pathway with AD.  
IL-10 gene, located on chromosome 1 is synthesized in central nervous system and its 
function is to limit the inflammatory response. Many SNPs have been identified in this 
gene; the most informative one is at position -1082 (Tagore et al. 1999). The presence 
of AA genotype in the promoter region of IL-10 gene increased the risk of developing 
AD and the rate of cognitive decline (Lio et al. 2003). Tumor necrosis factor α (TNF- α) 
is an inflammatory cytokine involved in the local immune response occurring in the 
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central nervous system of AD patients. TNF-α SNP in the promoter region −308 G/A is 
associated with AD (Lio et al. 2006). 
IL-1β gene by affecting brain immune responses may influence the age at onset of the 
disease, AD progression and survival. This cytokine is expressed by activated microglia 
in AD (Sheng et al. 1996). A polymorphism at position -511 in the promoter region of 
IL-1 beta gene is present and the TT genotype has been associated with an increased 
risk of AD (Licastro et al. 2000, Chiappelli et al. 2006). 
Hydroxy-methylglutaryl-coenzyme A reductase (HMGCR) is the rate limiting enzyme 
in the synthesis of cholesterol. A SNP in the promoter region (-911) of this gene was 
investigated in a case-control study and appears to be linked to both AD risk and disease 
progression (Porcellini et al. 2007). 
Even if it is very important to find new SNPs associated to AD, the study of SNP on 
limited sets of patients is not very informative. This situation has changed to some 
degree since the advent of massively parallel genotyping techniques that now allow the 
sequencing of the genomes of a large number of subjects at varying degrees of 
resolution. In the last few years, the most popular genetic approach has been based on 
genome-wide association studies (GWAs) where up to one million genetic markers are 
simultaneously genotyped and assessed for potential correlations with the disease risk 
and other phenotypic variables.  
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Genome wide association studies 
Between 2007 and 2009, several GWAs in AD were performed and they improved our 
knowledge of the genetics link with AD (Lambert et al. 2011). 
The two large GWAs from the UK (Harold et al. 2009) and France (Lambert et al. 
2009) found sets of genes located in different chromosome as shown in Table 2. 
 
Gene  Chromoso
me 
GWA studies 
CEACAM 16 Carcinoembryonic antigen-related 
cell adhesion molecule 16 
19 Lambert et al 2009, 
Harold et al 2009 
BCL3 B-cell CLL/lymphoma 3 19 Lambert et al 2009, 
Harold et al 2009 
PVRL2 Poliovirus receptor-related 2 
(herpesvirus entry mediator B) 
19 Lambert et al 2009, 
Harold et al 2009 
TOMM40 Translocase of outer mitochondrial 
membrane 40 homolog (yeast) 
19 Lambert et al 2009, 
Harold et al 2009 
APOE Apolipoprotein E 19 Lambert et al 2009, 
Harold et al 2009 
APOC1 Apolipoprotein C1 19 Lambert et al 2009, 
Harold et al 2009 
CLU Clusterin 8 Lambert et al 2009, 
Harold et al 2009 
CR1 Complement receptor 1 1 Lambert et al 2009, 
Harold et al 2009 
CLEC 16A C-type lectin domain family 16 
member A 
16 Lambert et al 2009, 
Harold et al 2009 
PICALM Phosphatidylinositol binding 
clathrin assembly protein 
11 Lambert et al 2009, 
Harold et al 2009 
 
Table 2. Cluster of genes from GWA studies associated with AD risk.   
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The first set of genes was located in close vicinity of the APOE locus on chromosome 
19 and consisted of the poliovirus receptor-related 2 (PVRL2) or nectin-2 (NC-2), 
apolipoprotein E (APOE), the translocase of outer mitochondrial membrane 40 homolog 
(TOMM40), the glycoprotein carcinoembryonic antigen related cell adhesion molecule-
16 (CEACAM-l6), and Bcell/lymphoma-3 (Bcl-3) genes. Genes in the second set were 
located in different chromosomes: APOJ or clusterin on chromosome 8; the 
complement receptor l (CR-l) on chromosome 1, and C-type lectin domain family 16 
member A (CLEC 16A) on chromosome 16. Polymorphic variations in each of these 
genes were individually associated with AD (P values ranging from 10
−16
 to 10
−5
). 
Moreover, three novel AD genes, i.e., CLU (clusterin or apolipoprotein J), CR1 
(complement component (3b/4b) receptor 1), and PICALM (phosphatidylinositol 
binding clathrin assembly protein) were also confirmed to be associated with AD risk. 
These loci have since received overwhelming support from independent follow-up 
studies (Carrasquillo et al. 2010, Jun et al. 2010) and currently rank at the very top of 
the AlzGene meta-analyses, directly following APOE. In addition, there are several 
other SNPs in each of these loci showing highly significant association (p values < 1 × 
10
−5
) with AD risk, leaving essentially no doubt that variants in these or nearby genes 
represent genuine AD susceptibility loci.  
It is important to note, the risk effect exerted by the new GWA SNPs is small, i.e., they 
confer a mere ~ 0.10-fold to 0.15-fold increase or decrease in AD risk in carriers versus 
non carriers of the associated alleles.  It is important to note that the presence of the 
APOE ε4 allele is associated with a nearly 4-fold increase in AD risk. 
A third new set of genes has emerged in a more recently GWA studies (Hollingworth et 
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al. 2011, Naj et al. 2011) as summarized in Table 3.  
 
Table 3. Second cluster of genes from GWA studies associated with AD risk.   
 
Interestingly, the one overarching common finding emerging from all published AD 
GWAs to date is the highly significant association between increased AD risk and the 
presence of the APOE ε4 allele (Bertram 2011). 
In fact, GWAs approach is different from the classical genetic studies, because the 
majority of today’s genetics projects are not aimed at the identification of rare, disease-
causing mutations, but instead at finding common DNA variants or SNP that can 
modify susceptibility to high-prevalence disorders. The GWA approach is solved by 
genotyping hundreds of thousands SNPs on a genome wide scale (eg, in affected cases 
and healthy controls). Genotyping is followed by statistical analyses of data base, which 
probe for significant differences in allele or genotype frequencies. In addition to not 
being limited to some predefined set of candidate genes, the GWAs approach has 
several other advantages that increase the validity of the emerging results, eg, the ability 
to adjust for otherwise difficult-to-detect population substructure, to perform in silico 
Gene  Chromos
ome 
GWA studies 
ABCA7 ATP-bonding cassette, sub family A, 
member 7 
19 Hollingworth et al 2011, 
Naj et al 2011 
MSA4 Membrane spanning A4 11 Hollingworth et al 2011, 
Naj et al 2011 
CD2AP CD2 associated protein 6 Hollingworth et al 2011, 
Naj et al 2011 
CD33 Cluster of differentiation 33 19 Hollingworth et al 2011, 
Naj et al 2011 
EPHA1 Ephrin receptor A1 7 Hollingworth et al 2011, 
Naj et al 2011 
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fine -mapping based on genotype imputation, and to serve as a “replication engine” for 
proposed associations from other datasets without having to perform additional 
experiments. Instead, owing to the very large number of markers tested in typical 
GWAs, many SNPs are bound to show significant effects by chance alone, which has to 
be taken into account when reporting and interpreting GWAs results (Bertram 2011). 
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Environmental factors and genetic interactions 
AD is a complex multifactorial disease resulting from the interaction of several 
determinants: principally genetic and environmental, all mostly unknown. 
Environmental factors might play a role in this complex disease. Environmental risk 
factors may accumulate with advancing age and play the role of multiple triggers of the 
disease in the susceptible brain; however these factors are still largely unravelled in AD. 
It is important to know that environmental factors may also interact with genetic risk 
factors in a complex interplay that might be the central node to a correct interpretation 
of pathogenic mechanisms leading to age-related neurodegeneration and dementia. 
However, it is essential to start or refine the search for environmental components 
associated to AD, in order to reveal such a complex cross talk with the partially known 
genetic risk factors predisposing to the disease.  
A viral etiology, involving in particular herpes virus in AD, has been already 
investigated (Wozniak et al. 2009, Itzhaki et al. 2008, Carter 2008, Burgos et al. 2006, 
Mori et al. 2004).  
We suggest that infective agents of CNS, such as viruses of the herpes family, are the 
probable link for all SNPs found associated with AD from GWA studies and the view 
presented here supports the notion of an infective etiology of sporadic AD (Porcellini et 
al. 2010, Licastro et al. 2011). 
 
• NC-2, also known as herpes virus entrance-B (HveB) or poliovirus receptor-relate 
protein-2, is a member of the immunoglobulin super family, is expressed in a variety of 
cell tissues, including neurons, belongs to the cadherin adhesion molecules (Takai et al. 
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2003) and mediates the entry of herpes simplex viruses (HSV) (Spear 2004). The 
glycoprotein D (gD) of HSV is the ligand for NC-2 and one of several HSV binding 
proteins that are essential for fusion to the human target cell and viral entering (Spear 
2004). Gene variants in the human NC-2 gene might affect individual susceptibility to 
HSV infection of the brain by influencing virus cell entry and cell-to cell virus 
spreading. 
• APOE 4 allele is a well established genetic risk factor for AD and it has been also 
confirmed in the European GWA study (Lambert at al. 2009). ApoE protein may affect 
Aβ deposition. However, APOE 4 allele has been also shown to influence: susceptibility 
to viral infections (Mahley et al. 2009), human immune deficiency virus (HIV) cell 
entry in vitro, HIV disease clinical progression (Burt et al. 2008), recurrent genital 
herpes in patients co-infected by HSV-2 and HIV (Jayasuriya et al. 2008) and 
progression of experimental ocular lesions induced by HSV-1 (Bhattacharjee et al. 
2008). Therefore, APOE 4 allele association with AD might also influence the 
susceptibility to virus entry and spreading into neuronal cells. 
• TOMM-40 gene codes for a mitochondrial translocase. It is interesting to note that 
HSV DNAase such as the UL12 enzyme destroys the mitochondrial genome (Corcoran 
et al. 2009) by inducing rapid and complete degradation of mitochondrial DNA (Saffran 
et al. 2007). Gene variations at TOMM-40 gene might influence DNA digestion and 
mitochondrial damages induced by HSV DNAase and other less defined virus 
dependent mechanisms. 
• CEACAM-16 belongs to a family of gene coding for adhesion molecules related to 
cancer replication, such as the carcinoembryonic antigen (CEA), and has been recently 
Introduction 
 
22 
 
shown to regulate apoptosis in early tumor development by affecting caspase-l/3 
activation (Nittka et al. 2008). 
• Bcl-3 is an oncogene and is also involved in cell replication and apoptosis. Apoptosis 
may act as a primitive immune response and is a potent host defense mechanism. It is 
known that HSV is able to both induce and suppress apoptosis in infected cells. In 
particular HSV was shown to inhibit initially induced apoptosis in neuronal cells via a 
caspase-3 dependent pathway (Wang et al. 2005). Moreover, Bcl-2 protein was able to 
block HSV induced apoptosis in human hepatocytes (Galvan et al. 2000). Therefore, 
gene polymorphism in both CECAM-16 and Bcl-3 genes might influence individual 
susceptibility to apoptosis regulation induced by HSV and favor virus spreading in the 
central nervous system (CNS). 
• The APOJ, also known as clusterin, is a modulator of complement activation. 
Complement biosynthesis and activation occurs in neurodegenerative diseases such as 
AD (Francis et al. 2003) and the cytolytic activity of complement components is 
important for virus neutralization. ApoJ is synthesized in the CNS and is present in 
amyloid plaques (Calero et al. 2000). Polymorphism in APOJ gene might influence 
virus lytic defences by regulation of complement activation. 
• CR1 is a complement receptor which binds different complement components (C3b, 
C3d, and C2a). HSV family (especially alpha herpes) expresses a member of gC protein 
family that is able to bind heparan sulphate and the C3b component of the complement 
system (Spear 2004). Genetic variation in CR1 and CR2 receptors might affect 
individual capacity of virus clearance via C3 activation and C3b binding to the HSV. 
APOJ and CR1 genes might be illustrated as a synergistic gene cluster and influence 
brain virus defences such as complement activation, virus lysis and clearance. 
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• CLEC-16A gene codes for a C-type lectin domain receptor. Lectin-like receptor, such 
as mannose receptor, recognizes and binds sugar moieties on pathogen glycoproteins. 
No data are on record regarding CLEC-16A and HSV or other viruses. However, gene 
polymorphisms in the CLEC-16A gene might influence individual ability to recognize 
and bind virus glycoproteins. 
• ABCA7 is highly expressed in the brain, especially values in hippocampal CA1 
neurons (Kim et al. 2006) and microglia (Jehle et al. 2006) and regulates the efflux of 
lipids from cells to lipoproteins.  Moreover ABCA7 influences the quality of lipoprotein 
by interacting with APOA1 molecules especially in female, since this gene is involved 
in the assembly reaction of high density lipoprotein (HDL) (Ikeda et al. 2003) and 
controls heterogeneity of HDL (Hayashi et al. 2005). It is known that certain viruses can 
circulate in biological fluids bound to lipoproteins, for instance hepatitis C virus 
particles circulates associated with plasma lipoproteins (André et al. 2005). Therefore, 
the type of lipoproteins and lipids might influence virus transport to a given tissue and 
its circulation within the brain especially in women; incidence and prevalence of AD 
being higher in women. This gene also affects the efficiency of phagocytosis of 
apoptotic cells by monocytes cell lineage (Kim et al. 2005) and clearance of apoptotic 
virus infected cells (Jehle et al. 2006).  Therefore, ABCA7 variants might also influence 
clearance of infected cells from the brain.  
• MSA4 gene belongs to a genetic cluster located on chromosome 11 and encodes for 
the beta sub-unit of high affinity IgE receptor (Kinet et al. 1988, Crocker  et al. 2007);  
this molecule is a component of an oligomeric cell surface complex involved in signal 
transduction in different cell lineages (Liang et al. 2001). The MSA4 cognate protein 
has been involved in antiviral responses in human plasmocytoid or lung dendritic cells 
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(Gill et al. 2010, Grayson et al. 2007). Furthermore, CD23 or Fc-epsilon IIIR play a role 
in astrocyte inflammatory response during HIV-1 encephalitis (Dugas et al. 2001) and 
HIV-1 infection induces an impaired regulation of the IgE Fc-epsilon RI network 
(Marone et al. 2001).  Therefore, this gene might influence virus entrance in neuronal 
cells and virus infectivity might in turn affect the expression of this membrane complex.    
• CD2AP gene is located on chromosome 6 and codes for a member of a novel family of 
scaffold/adaptor proteins, expressed on several cell types and regulates the actin 
cytoskeleton (Lynch et al. 2003). CD2AP plays an important role in antivirus defences, 
since it regulates transportation and fusion of cytoplasmic granules in NK cells (Ma et 
al. 2010). Moreover this molecule also affects selective activation of survival pathways 
and repression of apoptosis signalling by TGF-beta (Schiffer et al. 2004). CD2AP might 
play multiple roles by regulating defence mechanisms against virus infectivity and cell 
sensitivity to apoptosis induced by the virus infection.  Finally, CD2AP, by affecting 
early endosome morphology and traffic between early and late endosomes (Cormont et 
al. 2003), might disturb APP metabolism and amyloid deposition.   
• CD33 gene is on chromosome 19 and codes for a member of the sialic-acidic-binding 
immunoglobulin like lectin or SIGLEC family that promotes cell-cell interactions and 
regulates immune functions of both innate and adaptive immunity (Tateno et al. 2007). 
Human cytomegalovirus latent infection induced the up-regulation of the MCP-1 
molecule in a restricted subset of CD33 positive myeloid progenitor cells and this 
mechanism may contribute to virus dissemination (Stern et al. 2008, Hahn et al. 1998). 
Human herpes virus 7 also induced an up-regulation of CD33 in cultured human cells 
(Mirandola et al. 2000). Moreover, microarray analysis of blood mononuclear cells from 
HIV-1 positive patients on retroviral therapy showed an over expression of CD33 
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molecule (Wu et al. 2008). In liver Kupffer cells infected by HCV over-expressed the 
CD33 molecule (Dolganiuc et al. 2007). Once again one gene might affect multiple 
steps involved in herpes infectivity and individual susceptibility to virus infection.   
• EPAH1 is a member of the ephrin receptor sub-family of tyrosine-kinases and 
mediates cell and axon guidance, synaptic development and plasticity (Coulthard et al. 
2001, Yamazaki et al. 2009). This molecule is also implicated in apoptosis (Duffy et al. 
2008) and inflammatory response regulation (Ivanov et al. 2006). EPAH1 might be 
implicated in antivirus resistance by affecting both apoptosis impairment induced by the 
virus infection, the efficiency of the host immune responses and synaptic plasticity of 
infected neurons. 
Our hypothesis describes sets of genes (as shown in Table 1 and 2) that may constitute a 
gene cluster of susceptibility for AD by affecting different mechanisms involved in 
virus entrance or resistance to viruses infection.  
We suggest that infective agents of CNS, such as viruses of the herpes family, are the 
probable link for all SNPs found associated with AD from recent GWA studies and the 
view presented here supports the notion infective factors are associated with the clinical 
history of  sporadic AD. 
We argue that the concomitant presence of several SNPs in these genes in the same 
individual might represent a genetic signature of AD and further reinforce our 
hypothesis that such genetic trait predisposes to AD via complex and diverse 
mechanisms each contributing to the differential individual brain susceptibility to viral 
infections.  
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Herpes viruses 
The Herpesviridae are a large family of DNA viruses that cause diseases in animals and 
humans. Herpes viruses share a common structure: are composed of relatively large 
double-stranded, linear DNA genomes encoding 100-200 genes encased within an 
icosahedral protein cage called capsid, which is itself wrapped in a protein layer called 
tegument containing both viral proteins and viral mRNAs and a lipid bilayer membrane 
called envelope. This whole particle is known as a virion. The name herpes comes from 
the Latin herpes which, in turn, comes from the Greek word herpein which means to 
creep. This reflects the creeping or spreading nature of the skin lesions caused by many 
herpes virus types. Once a patient has become infected by herpes virus, the infection 
remains for life. The initial infection may be followed by latency with subsequent 
reactivation. Herpes viruses infect most of the human population and persons living past 
middle age usually have antibodies to most of the above herpes viruses. The 
Herpesviridae are currently divided into three sub-families, as shown in the Table 3 
(Hunt, Virology, chapter eleven, HERPES VIRUSES, Microbiology 5th Ed). 
Human 
herpes 
type 
Name Sub Family Target cell type Latency Transmission 
1 
Herpes simplex-1 
(HSV-1) 
α-herpesvirinae Mucoepithelia Neuron Close contact 
2 
Herpes simplex-2 
(HSV-2) 
α-herpesvirinae Mucoepithelia Neuron 
Close contact 
usually sexual 
3 
Varicella Zoster 
virus (VSV) 
α-herpesvirinae Mucoepithelia Neuron 
Contact or 
respiratory route 
4 
Epstein-Barr 
Virus (EBV) 
γ-herpesvirinae 
B lymphocyte, 
epithelia 
B 
lymphocy
tes 
Saliva 
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Table 3. Herpes virus family. 
 
It is interesting to note that many herpes viruses share the ability to become latent in the 
infected host and eventually latently infect neurons. However, investigations focused on 
different viruses of the herpes family, such as cytomegalovirus (CMV), Epstein-Barr 
virus (EBV) or Human herpes virus 6 (HHV-6), in AD are scarce. 
CMV is ubiquitously distributed in human population and is the most frequent infection 
of the brain in infants with the congenital virus transmission or in immune compromised 
patients (Tsutsui et al. 2008). Postnatal acute CMV infection is usually asymptomatic, 
but once established, the virus remains latent in blood monocytes (Pawelec et al. 2009). 
CMV has also been associated with other chronic diseases of aging, including 
cardiovascular disease, cognitive decline and cancer. The specific mechanisms 
responsible for these associations have not been fully understood, but they are likely to 
have an immune and inflammatory component (Simanek et al. 2011). The serological-
5 
Cytomegalovirus 
(CMV) 
β-herpesvirinae 
Epithelia, 
monocytes, 
lymphocytes 
Monocyte
s, 
lymphocy
tes and 
possibly 
others 
Contact, blood 
transfusions, 
transplantation, 
congenital 
6 
Herpes 
lymphotropic 
virus (HHV-6) 
β-herpesvirinae 
T lymphocytes and 
others 
T 
lymphocy
tes and 
others 
Contact, 
respiratory route 
7 
Human herpes 
virus-7 (HHV-7) 
β-herpesvirinae 
T lymphocytes and 
others 
T 
lymphocy
tes and 
others 
Unknown 
8 
Human herpes 
virus-8 (HHV-8)  
Kaposi's sarcoma- 
associated herpes 
virus (KSHV) 
γ-herpesvirinae Endothelial cells Unknown 
Exchange of 
body fluids? 
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conversion to CMV may vary over the years, ranging between 0.5 to 1.5% per year, and 
CMV is responsible of the age-associated immune changes in the elderly which lead to 
a reduction in the number of naive T cells (Rymkiewicz et al. 2012). An increased rate 
of cognitive decline over a 4-year period in subjects with elevated CMV antibody levels 
has been reported (Aiello et al. 2006). Previous work upon brain frontal and temporal 
cortex samples found that both AD patients and elderly healthy subjects were positive 
for CMV with not statistically significant difference (Lin et al. 2002). CMV was found 
in the brain of a greater proportion of patients with vascular dementia than normal 
elderly; these findings suggested a role for this virus in the disease (Itzhaki et al. 2004).   
EBV infects more than 95% of human beings within first decades of life. The virus 
causes acute infectious mononucleosis in a minority of immune competent subjects, 
while the majority develops a lifelong asymptomatic infection and the virus remains 
latent in B-lymphocytes. EBV is involved in the development of several diseases such 
as Burkitt lymphoma, Hodgkin lymphoma and nasopharyngeal carcinoma (Kutok et al. 
2006). 
Moreover, EBV seems to be involved in the pathogenesis of various neurological 
diseases, such as  encephalitis, neuritis, myelitis, cerebellitis, acute disseminated 
encephalomyelitis, or central nervous system (CNS) lymphoma in patients with the 
immunodeficiency virus (HIV) infection (Kleines et al. 2011). EBV has been also 
associated with the pathogenesis of the multiple sclerosis, but its role in the disease is 
still unclear (Lassmann et al. 2011). To our knowledge no data regarding the presence 
of EBV in the AD peripheral blood are on records. HHV-6 is a neurotropic virus and 
has been associated with multiple neurological diseases including seizures, encephalitis, 
mesial temporal lobe epilepsy and multiple sclerosis (Yao et al. 2010). HHV-6 has been 
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found in a higher proportion of AD brains than age-matched control (CTR) brains (Lin 
et al. 2002). However, these findings were not confirmed by another investigation 
(Hemling et al. 2003). Moreover we were also interested in the immune response of the 
host to infections, since with aging the immune system undergoes changes following a 
process called immunosenescence, leading to an increased susceptibility of older adults 
to develop, not only infectious disease, but also AD, osteoporosis, cancer and 
autoimmunity (Lang et al. 2012).  
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Inflammation 
The hypothesis that inflammation may participate in Alzheimer's disease pathogenesis 
was first articulated about 20 years ago, and despite two decades of work, many of the 
central questions regarding the inflammatory response in the Alzheimer's disease brain 
remain unanswered. 
Inflammatory response is a very complex process; slightly regulated that involves the 
synthesis and the release of numerous factors such as cytokines, inflammatory 
mediators, histamine, prostaglandin and also some hormones (McGeer and McGeer 
1998). 
Epidemiological investigations also support the notion that inflammation may play a 
significant role in AD. In fact, head injuries in early adulthood may be associated with 
increased risk of AD in late life, and the routine use of non steroid anti inflammatory 
drugs is associated with a decreased incidence of AD (Plassman et al. 2000). 
Inflammation is associated with the degeneration of brain areas; in fact, senile plaques 
in AD brains are associated with reactive astrocytes and activated microglial cells and 
cytokines and acute phase proteins are over expressed in microglia and astrocytes 
surrounding neuropathological lesions in AD brains. Inflammatory factors, such as 
cytokines, chemokines, complement components and acute phase proteins co localize as 
secondary components in neuritic or senile plaques or are over-produced in AD brains, 
and activated microglia surround senile plaques and areas of neurodegeneration 
(McGeer and McGeer 1998, Licastro 2002). There is accumulating evidence that Aβ 
peptide may promote or exacerbate inflammation by inducing glial cells to release 
immune mediators. Moreover, microglial and astroglial cells surrounding mature 
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plaques in AD brains have been found to express activation markers (Licastro et al. 
2010). 
In AD brain, moreover, inflammatory response appears to be alterated:  levels of 
cytokines such as TNF, IL-1, IL-6, IL-8 IL-10 and some interferons seem to be elevated 
(Baumann et al. 1994).  
Inflammation clearly occurs in pathologically vulnerable regions of the AD brain, and it 
does so with the full complexity of local peripheral inflammatory responses. On the 
other hand, several other investigations have shown increased blood levels of some 
cytokines, such as IL-1β and IL-6, and acute phase proteins as α-1-antichymotrypsin 
(ACT) in patients with clinical AD (Licastro et al. 2000, Licastro et al. 2003b). 
Therefore, altered immune responses in the brain and the peripheral blood appeared to 
be associated with the disease. Finally, ACT plasma levels also correlated with the 
degree of cognitive impairment in AD patients from a case-control study (Licastro et al. 
2000), suggesting that peripheral markers of inflammation or impaired immune 
responses could be used for monitoring the progression of the disease. Moreover, 
elevated levels of IL-6 in both brain homogenates and peripheral blood from AD 
patients have been reported (Licastro et al. 2003). These findings suggested that an 
important, but still largely unknown, interplay between brain and peripheral immune 
responses existed in the diseases.  
Moreover, our previous investigations also showed that SNPs in the promoter region of 
several genes controlling for different cytokines synthesis and release, such as IL-1α, 
IL-1β, IL-6, IL-10, interferon-γ (IFN-g) and TNF-α were differentially associated with 
the risk of AD (Licastro et al. 2007). These results may also be explained by the virus 
infection hypothesis, since individual differential ability to mount an effective immune 
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response can influence the control of the virus latency and individual susceptibility to 
virus re-infection both in peripheral tissues and brain. 
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Multi factorial interactions in the pathogenesis 
pathway of Alzheimer’s disease: 
a new risk charts for prevention of dementia. 
AD is a chronic and progressive neurodegenerative disorder and it is the most common 
neurodegenerative disorder in the industrialized world.  
Up to now, the incidence of AD is rising sharply and extensive research has focused on 
the pathogenetic mechanisms of the disease; however, despite the urgency for effective 
preventive and therapeutics measures many questions remain unanswered. 
The pathophysiological process of AD begins years, if not decades, before the diagnosis 
of clinical dementia (Morris 2005), so it is critical to better define the biomarker and/or 
cognitive profile that best predicts progression from the preclinical to the clinical stages 
of MCI or cognitive impairment not dementia  (CIND) and AD dementia. 
In this innovative article, a new statistical approach was used to evaluate the 
relationship among genetic, clinical and classical risk factors in AD: the Auto 
Contractive Map algorithm (AutoCM). This method is based on an artificial adaptive 
system able to define the strength of the associations of each variable with all the others 
in any dataset.  This novel data mining, the AutoCM algorithm, (Hamsten et al. 2008) 
was aimed to explore the concomitant association of different variables with AD and the 
potential relationships among variables in a multi factor network relevant for the 
disease. The ultimate goal of this data mining model was to discover hidden trends and 
new associations among variables, since this algorithm was able to create a semantic 
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connectivity map in which non linear association were preserved and explicit 
connection schemes were described. 
This approach describes a context typical of living systems where a continuous time 
dependent complex change in the variable value is present. After the training phase, the 
matrix of the AutoCM represents the warped landscape of the dataset. A simple filter 
(minimum spanning tree by Kruskal) to the matrix of AutoCM system was introduced; 
this approach shows the map of relevant connections between and among variables and 
the principal hubs of the system. Hubs can be defined as variables with the maximum 
amount of connectivity in the map (Campisi et al 2009). The AutoCM was applied to 
elaborate biological and clinical data (in particular different genotypic, phenotypic, 
clinical, pharmacological or habit variables) to find relationship between variables and a 
possible hierarchy in the relevance of each variable with AD, CIND and vascular 
dementia (VD) (Figure 3). 
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Figure 3. Connectivity map of 42 epidemiological, genetic and clinical variables showing different output 
such as AD, CIND, VD and control case. 
 
For these reasons we applied this new statistical method to analyze the database 
generate during the Conselice Study of Brain Aging. This study is a population-based 
prospective investigation focused on a homogeneous elderly (65 year old or older) 
population from Northern Italy (Ravaglia et al. 2001).  
Participants were interviewed, medically examined and cognitively evaluated in 1999 
and divided in 4 groups: AD, VD, CIND subjects and controls (CTR). 
CIND, as MCI, is a clinical situation that defines the transitional period between normal 
aging and dementia and is used to define impairments of any objective cognitive 
domains by neuropsychological testing in the absence of dementia.  
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As shown in the figure, data presented here found four major biological hubs: 1) low 
blood cholesterol, 2) high BMI index, 3) low blood HDL and 4) low blood folate. 
CIND, as expected, were associated with a lower age at onset, however age was closely 
correlated to prevalent AD cases confirming that age is the major risk factor in AD.  
Variables as APOEε4 allele, increased Vitamin B12 and ACT levels, and presence of 
mutated allele of several inflammatory genes were related to the main hubs underlining 
the implication of all these factors with the disease.  
As expected, cognitive healthy status, in the map, is far from AD, VD and CIND 
condition. 
Our findings showed four major connecting nodes from the Conselice data base; these 
hubs linked apparently different factors to cognitive impairment and dementia via 
cholesterol, cholesterol gene dependent pathway, BMI and age.  
A new association among different immunological factors and lipid metabolism with 
incident dementia has also emerged. 
This statistical analysis is innovative because, for the first time, it takes in consideration 
that AD is a multi-factorial disease and allowed us to look at the AD, CIND and VD 
with a more complex approach than the classical statistical methods. 
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Alzheimer's disease gene signature says: 
beware of brain viral infections. 
 
AD represents one of the most important causes of disability in the elderly and therefore 
one of the major ages associated health and social problem.  
As reported above, AD is a chronic neurodegenerative disorder clinically merging when 
the progressive neuronal death is in an advanced phase and up to date no effective 
medication is available. In fact, AD is still a non curable human disorder.  
Recent GWA studies conducted by many European research laboratories reported that 
the allele 4 of APOE gene CLU and CR1 have been strongly correlated to AD with a 
very high association probability (p~10
-10
). Moreover, in this report, also a limited 
number of genes were highly associated (p ~ l0
-5
) with the disease (Lambert et al. 2009, 
Harold et al. 2009). 
Genetic and environmental factors interact in a complex interplay that might be the 
central node to a correct interpretation of pathogenic mechanisms leading to age-related 
neuro-degeneration and dementia. 
In particular, some initial observations indicated that the DNA of Herpes simplex virus 
type 1 (HSV-1) was found more frequently in the cerebral cortex of patients with AD 
than non-demented controls (Itzhaki RF et al. 1997).  
The presence of viral DNA was particularly frequent in AD patients carrying the allele 
e4 of APOE gene (Itzhaki RF et al. 2006).  
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In this article we hypothesized that a gene cluster may predispose to AD via complex 
and diverse mechanisms each contributing to an increase of individual susceptibility to 
brain viral infections.  
The first set of genes was located in close vicinity of the APOE locus on the 
chromosome 19 and consisted of the poliovirus receptor-related 2, APOE gene, the 
translocase of outer mitochondrial membrane 40 homolog (TOMM-40), the 
glycoprotein carcinoembryonic antigen related cell adhesion molecule-l6 (CEACAM-l 
6) and B-cell/lymphoma-3 (Bcl-3) genes (Table 4). Genes in the second set were located 
on different chromosomes: clusterin (CLU) on chromosome 8, complement receptor 1 
(CRl) on chromosome 1, and C-type lectin domain family 16 member A (CLEC-16A) 
on chromosome 16.  
 
 
Table 4. Gene cluster surrounding the APOE gene on human chromosome 19. 
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These genes, as reported in the introduction, maybe linked to different herpes simplex 
viral mechanisms and we argue that the concomitant presence of several polymorphisms 
of these genes in the same individual might represent a genetic signature of AD.  
This hypothesis is supported also by other investigations focused on HSV infection in 
AD brains (Itzhaki et al. 2008; Carter 2008; Wozniak et al. 2009).  
HSV1 encodes a glycoprotein (glycoprotein B, gB) that contains a sequence that is 
highly homologous to a segment of Aβ (Cribbs et al. 2000) and HSV1 associates with 
APP during axonal transport, and might thereby affect APP cellular distribution, leading 
to altered APP processing (Satpute-Krishnan et al. 2003). Moreover, Wozniak et al. 
2009 have demonstrated a co-localization of herpes simplex virus DNA within amyloid 
plaques in temporal and frontal cortices (Wozniak et al. 2009). 
Reactivation of HSV-1 in the brain was also found in patients with familial AD who 
showed increased viral DNA and protein expression in cortical neurons (Mori et al. 
2004). 
Therefore, brain infection by reactivated latent viruses might be one of the primus 
movens inducing progressive neuronal loss, astroglia activation, and, impaired APP 
transport along the axons.  
Moreover, viruses of the HSV family are the most probable pathogen candidates for 
brain reactivation in old age, since they have a well known ability to escape peripheral 
immune responses by invading neurons. Recently has been reported that Aβ peptide 
showed an anti-microbial activity and acted as a defense molecule of the innate 
immunity, and this observation is compatible with the hypothesis of viral association 
with AD etiology and pathogenesis (Soscia et al. 2010). The accumulation of Aβ and 
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plaque deposit may derive by an over-production of Aβ peptides directed against a viral 
invader of the brain. 
In conclusion, present findings suggest that during ageing virus reactivation may be 
more frequent in the elderly showing a genetic signature predisposing to an increased 
susceptibility for HSV and other virus infections of the brain. In these subjects the 
microorganisms are more likely to induce limited, segmental and chronic sub-clinical 
pseudo-encephalitis resulting in a progressive neurodegeneration.  
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Gene signature in Alzheimer's disease 
and environmental factors: 
the virus chronicle. 
The main pathological features of AD are the presence of extracellular senile plaques 
formed of Aβ peptide and the presence of intracellular deposition of neurofibrillary 
tangles as central mechanism leading to neurodegeneration and cognitive impairment. 
However, therapeutic approaches focused on reducing amyloid load and plaques 
depositions have been unsuccessful. Other mechanisms might be closely related with 
the etiology and pathogenesis of sporadic AD.  
Two years after the publication of Lambert et al. and Harold et al. GWAs other groups 
published a new set of genes associated with AD risk: ABC7A, MSA4, CD2AP, CD33, 
EPHA1(Hollingworth et al. 2011, Naj et al. 2011). Their potential relevance in virus 
infection and AD has already been discussed in the introduction. 
Despite of the elevated numbers of patients and controls from AD GWA studies, each 
single SNP showed a modest OR for the disease, usually less than 2.0. These findings 
are suggestive of the following considerations:  
1) Interactions among different SNPs in diverse genes might be more informative than a 
single SNP; 
2) None of these genes alone is causative for the diseases; 
3) All described genes are however involved in different aspects of AD pathogenesis 
and/or clinical history;  
4) Environmental factor(s) might trigger several of these genes; 
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5) Many of these genes upon activation by environmental factor(s) would turn on or 
influence other genes that would affect secondary pathogenetic mechanisms in the brain 
such as apoptosis, immune responses, cholesterol synthesis and transportation, and 
oxidative stress. 
 
It might be that those other genes may also play a role in AD by influencing virus 
latency and infection susceptibility. 
SNP in the promoter gene of the ACT gene and ACT plasma levels correlated with 
cognitive decline (Porcellini et al. 2008) was associated with increased risk of AD, fast 
cognitive deterioration and elevated levels of plasma levels of the cognate protein 
(Licastro et al. 2005).  
Elevated serum ACT from HIV-1 positive women has been found and its levels 
correlated with the viral load (Friis et al. 2003). 
Moreover previous investigations also showed that SNPs in the promoter region of 
several genes controlling for different cytokines synthesis and release, such as IL-1α, 
IL-1β, IL-6, IL-10, interferon-γ (IFN-γ) and TNF-α were differentially associated with 
the risk of AD (Licastro et al. 2007). These results may also be explained by the virus 
infection hypothesis, since individual differential ability to mount an effective immune 
response can influence the control of the virus latency and individual susceptibility to 
virus re-infection both in peripheral tissues and brain. 
It is also important to note that, up to now, most of the investigations have shown an 
association of HSV1 with AD (Burgos et al. 2006, Carter 2008, Itzhaki et al. 1997, 
Itzhaki et al. 2008, Wozniak et al. 2009). However, CMV and HSV-2 might play a role 
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in cognitive decline during aging or dementia in Down syndrome patients (Anneren et 
al. 1986, Aiello et al. 2006).   
Moreover HHV-6 was found in brain specimens of control elderly and AD patients, 
even if did not appear to be specifically associated with dementia (Hemling et al. 2003). 
Viruses may play multiple and unsuspected 
role in neurodegeneration of CNS and be the 
initial hit starting a vicious cycle leading after 
several years to irreversible brain decline. A 
flow chart representing the complex interplay 
among epidemiological, genetic, virus, and 
inflammatory factors inducing sub-clinical and 
chronic neuronal loss is reported in Figure 4. 
 
 
 
 
 
 
 
Figure 4. Schematic relationship among risk 
factors related to brain infections during age. 
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Herpes viruses in Alzheimer's disease: 
relation with the progression of the disease. 
 
AD is a multifactorial disease where genetic factors and environmental factors interact 
in a complex interplay that might be the central node to a correct interpretation of 
pathogenic mechanisms leading to age-related neurodegeneration and dementia. 
Recently published genetic data from GWA studies from several thousand AD patients 
and controls (CTR) (Lambert et al. 2009, Harold et al. 2009, Hollingworth et al. 2011, 
Naj et al. 2011) indeed showed that a limited number of genes were highly associated 
(p>10-5) with the disease. However, the effect of a single SNP or gene, with the 
exception of the APOE gene, even in those above quoted large population studies was 
small. As discussed elsewhere, we argue that the concomitant presence of several SNPs 
in these genes in the same individual might represent a genetic signature of AD and 
further reinforce our hypothesis that such genetic trait may predispose to AD via 
complex and diverse mechanisms each contributing to a differential individual 
susceptibility for brain viral infections (Porcellini et al. 2010, Licastro et al. 2011). 
Viruses of the herpes virus family show features relevant to AD, since they infect a 
large proportion of human population, develop a latent form persisting for several years, 
are difficult to eliminate by immune responses especially when latency has been 
established and are able to infect neurons.  
In this article, we investigated the association between AD and herpes viruses infection, 
in particular we focused on CMV, EBV and HHV-6 both in peripheral blood and in 
brain tissue samples. 
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Patients with clinical diagnosis of AD and elderly CTR were enrolled from the 
longitudinal “Conselice study” (Ravaglia et al. 2001), cognitive performances were 
measured according to MMSE at the baseline of the study (1999) and at the end of the 
five year follow up (2004). Clinical diagnosis of AD followed the DMS IV and NINCS-
ADRDA criteria, as previously reported (Forti et al. 2001).  
Autoptic brain samples were collected from the Brain Bank of the Department of 
Neurosciences and Pathology at the University of California, San Diego (UCSD). 
Neuropathological diagnosis of AD was performed as previously described (Hansen et 
al. 1993). 
All samples analyzed for CMV DNA were negative, probably because these viruses 
don’t latently infected PBL and brain tissue, being monocytes the true site of virus 
latency (Gerna et al. 2004). However, serological data showed that almost 90% of 
samples were positive to CMV IgG antigens. 
Then we divided our samples in two groups CTR-CTR and CTR-AD based on the 
cognitive performances at the baseline of the study and at the end of the five year follow 
up where CTR-CTR remain cognitively healthy, while CTR-AD represented elderly 
that developed clinical AD at the end of the follow up. At the end of the follow up 42 
subjects remained cognitively healthy (CTR-CTR) and 24 subject suffered cognitive 
deterioration and developed clinical AD (CTR-AD).  
IgG CMV titers were significantly increased in those subjects who developed AD (fig 
N) 
1% of CTR and 45% of AD patients were positive for EBV DNA (p=0.05; OR 1.843), 
and the difference between CTR (4.4%) and AD (23.1%) for the presence of HHV-6 
DNA was statistically significant (p=0.002; OR=6.5). 
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In brain tissue the frequency of EBV and HHV-6 positivity was as follows: 4. 6% of 
brain samples were positive for EBV DNA (all samples were APOE ε4 carrier) and 
17% positive for HHV-6.  
Moreover, we described an association between the presence of EBV and HHV-6 DNA 
from PBL positivity with the cognitive deterioration and progression to AD. In fact, 
EBV and HHV-6 DNA positivity was higher in subjects who developed AD during a 
five year follow up.  
Moreover, EBV IgG plasma levels were higher in elderly subjects that developed 
clinical AD at the end of the five year follow up (Fig 5) 
 
  
 
 
 
 
 
Figure 5. IgG plasma levels specific for 2 different EBV antigen from CTR and AD at the 
beginning of the follow up (panel A and C) and at the end of five years follow up (panel B and 
D). CTR-CTR remained cognitively healthy, CTR-AD represented subject that developed AD. 
 
In the present report we showed that both EBV and HHV-6 DNA positivity along with 
CMV and EBV IgG plasma levels were associated with cognitive deterioration and 
progression to clinical AD. 
Our findings supported the notion that persistent cycles of latency and reactivation 
phases of these viruses may contribute to impair systemic immune response and induce 
A C B D 
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altered inflammatory process that in turn may affect cognitive decline during aging. 
These infectious agents appear to enter the brain of elderly subjects and induce brain 
chronic inflammation that contributes to neurodegeneration.   
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AD is a chronic and progressive neurodegenerative disorder and one of the most 
frequent diseases in the industrialized world. According to the World Health 
Organization it is estimated that there are currently nearly 35.6 millions of people 
worldwide suffer AD. AD develops for an indeterminate period of time before 
becoming clinically apparent, and it can progress undiagnosed for years. 
Late onset Alzheimer (LOAD) is the most common form of the disease and it is defined 
by the onset after the age 65 years. It is well established that the inheritance of the 
APOE ε4 allele is, after age, the single most potent and common risk factor for LOAD 
(Tanzi 2012).  
Moreover, many other genes, involved in different pathways, have been proposed as 
candidates for AD susceptibility. Our previews studies confirmed the association of 
several SNPs on the promoter region of genes involved in the inflammatory pathway 
and AD (Lio et al. 2003, Licastro et al. 2000, Porcellini et al. 2007). 
AD is a complex and multifactorial disease where clinical factor as inflammation, 
pathogens infections, environmental factors and genetics underlines the pathogenesis of 
the disease. 
A new statistical approach, AutoCM, has been presented. This statistical analysis is 
innovative because it takes in consideration that AD is a multifactorial disease. The goal 
was to create a network of genetic, phenotypic and clinical data that allow combining 
different type of variables.  
We tested this statistical analysis using Conselice database and we found specific four 
major connecting nodes that linked apparently different factors to cognitive impairment 
and dementia via cholesterol, cholesterol gene dependent pathway, BMI and age.  
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Classical statistical methods are not able to link genetic and clinical features since the 
heterogeneity among different variables. 
The classical genetic approach of focusing on one or a few candidate genes or one or 
few SNPs limits our ability to identify novel factors associated with AD. 
In fact, in the last few years, the most popular genetic approach is based on GWA 
studies, where up to one million genetic markers are simultaneously genotyped and 
assessed for potential correlations with disease risk and other phenotypic variables. 
My studies presented in this thesis showed several genes associated with AD risk that 
might be involved in herpes virus infection pathways.  
We just stressed the complexity of AD underlining the importance of the interaction 
between genetic and environmental factors. Pathogen infections, above all viral 
infections, have been previously associated to the pathogenesis of AD (Miklossy 2011). 
Our hypothesis suggests that virus and in particular herpes virus could reactivate in the 
brain when an individual becomes older, perhaps because of the decline in immune 
responses. Brain invasion by virus triggers various mechanisms that might lead to AD. 
Based on GWA results published on Nature Genetic we suggest that sets of genes were 
strongly associated with AD. The first set of genes was located in close vicinity of the 
APOE locus on chromosome 19 and consisted of the poliovirus receptor-related 2 or 
nectin-2 (NC-2), apolipoprotein E (APOE), the translocase of outer mitochondrial 
membrane 40 homolog (TOMM40), the glycoprotein carcinoembryonic antigen related 
cell adhesion molecule-16 (CEACAM-l 6), and Bcell/lymphoma-3 (Bcl-3) genes. Genes 
in the second set were located in different chromosomes: APOJ or clusterin on 
chromosome 8; the complement receptor l (CR-l) on chromosome 1, and C-type lectin 
domain family 16 member A (CLEC 16A) on chromosome 16. Polymorphic variations 
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in each of these genes were individually associated with AD (P values ranging from 
10−16 to 10−5) (Lambert et al. 2009). 
Moreover, three novel AD genes, i.e., CLU (clusterin; apolipoprotein J), CR1 
(complement component (3b/4b) receptor 1), and PICALM (phosphatidylinositol 
binding clathrin assembly protein) were published back-to-back (Harold et al. 2009). 
Then Hollingworth et al. and Naj et al. in 2011 published a new set of genes associated 
with AD risk: ABC7A (ATP-bonding cassette, sub family A, member 7), MSA4 
(Membrane spanning A4), CD2AP (CD2 associated protein), CD33 (Cluster of 
differentiation 33), and EPHA1 (Ephrin receptor A1).  
All these genes appear to be involved in the entry and/or in the replication of herpes 
viruses, in the cell-to cell virus spreading and also in the host immune resistance to 
virus infection.  
Our hypothesis is that the presence of allelic polymorphisms in these genes results in a 
genetic signature that might affect individual brain susceptibility to infection by viruses 
of the herpes family during aging, leading to neuronal loss, inflammation and amyloid 
deposition.  
Then, my work focused on the investigation of the presence of CMV, EBV and HHV-6 
in DNA samples from peripheral blood of a large cohort of patients with clinical 
diagnosis of AD and aged matched CTR and DNA samples from brain tissue of patients 
with neuropathological diagnosis of definitive AD.  
As far as we know, no report has investigated the presence of EBV DNA in association 
with AD. We found that a high proportion of AD patients showed EBV positive blood 
leukocytes. The presence of APOE ε4 allele appeared to increase the EBV positivity 
only in CTR. For the first time we found that almost the 6% of AD brain tissues were 
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positive to EBV and all subjects positive for EBV were also APOE ε4 carriers. Our 
findings suggest that the presence of EBV in the peripheral blood was a risk factor for 
AD and the APOE ε4 allele increased EBV positivity both in the blood and in the brain. 
HHV-6 is a neurotropic virus associated with different neurological diseases (Yao et al. 
2010). No data regarding HHV-6 DNA positivity in peripheral blood of AD have been 
reported. We showed that a higher proportion of AD patients than CTR were positive 
for this virus. 
Moreover, for the first time, we described an association between the presence of EBV 
and HHV-6 DNA from PBL positivity with the cognitive deterioration and progression 
to AD. In fact, EBV and HHV-6 DNA positivity was higher in subjects who developed 
AD during a five year follow up. 
To asses systemic immune responses in the healthy elderly and AD patients to these 
viruses, CMV, EBV and HHV-6 IgG plasma levels were tested. CMV and EBV IgG 
plasma levels were higher in elderly subjects that developed clinical AD at the end of 
the five year follow up. 
In the last article we showed, for the first time, that both EBV and HHV-6 DNA 
positivity along with CMV and EBV IgG plasma levels were associated with cognitive 
deterioration and progression to clinical AD. 
Our findings support the notion that persistent cycles of latency and reactivation phases 
of these viruses may contribute to impair systemic immune response and induce altered 
inflammatory process that in turn affect cognitive decline during aging. These infections 
agents appear to enter the brain of elderly subjects and induce brain chronic 
inflammation that contribute to neurodegeneration.   
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This thesis presents new data regarding environmental infective agents associated with 
AD. This form of dementia affects an increasing number in elderly both in 
industrialized and developing countries and is becoming an important social and 
economic problem. Unfortunately no effective therapies for this disease are now 
available and for this reason it is important to find new strategies for early intervention 
in the age-associated cognitive decline and the prevention of the occurrence of clinical 
AD.  
However, many questions remain un-answered; many aspects regarding viruses latency 
remain to be understood and more powerful methodological approach to detect latent 
viral forms needs to be developed.  
In fact, many molecular techniques are available to quantify viral infection clearing the 
active virus cycle, while, up to now, no molecular approaches have been specifically 
developed to quantify viral load during latency. I guess that this will be the future 
challenge in order to better define the association of herpes viruses infection and latency 
with AD and to better understand viral molecular pathways involved in AD clinical 
history and progression 
Further studies are needed to clarify the primary or secondary role of herpes virus 
infection in AD. Methodology improvements of methodology focused to investigate 
viral latency will help in better understanding the role of these pathogens in the AD. 
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